Picard Medical, Inc. is a medical technology company, which manufactures and sells the only U.S. FDA, and Health Canada approved implantable SynCardia TAH. The company is headquartered in Tucson, Arizona and currently employs 75 full-time employees. The company went IPO on 2025-08-29. SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.
최신 재무제표(Form-10K)에 따르면, Picard Medical Inc의 총 자산은 $12이며, 순손실입니다.
PMI의 주요 재무 비율은 무엇인가요?
Picard Medical Inc의 유동비율은 0.34이고, 순이익률은 -575, 주당 매출은 $0.05입니다.
Picard Medical Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Picard Medical Inc 주요 수익원은 Banking and Related Activities이며, 최신 수익 발표에서 수익은 55,372,000입니다. 지역별로는 United States이 Picard Medical Inc의 주요 시장이며, 수익은 55,372,000입니다.
Picard Medical Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Picard Medical Inc의 순손실은 $-23입니다.